We found that the addition of a YAP1 inhibitor to immunotherapy further enhanced anti-tumor activity and immune cell function, indicating the great potential of combined YAP1 and PD-L1 blockade in the clinical treatment of patients with the SCLC-Y subtype, an approach that is expected to improve the prognosis of SCLC patients. This evidence concerns the gene CD274 and small cell lung carcinoma.